Outset Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 04:10 pm EST
Share
Outset Medical, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 30.36 million compared to USD 27.76 million a year ago. Net loss was USD 46.18 million compared to USD 40.78 million a year ago. Basic loss per share from continuing operations was USD 0.93 compared to USD 0.85 a year ago. Diluted loss per share from continuing operations was USD 0.93 compared to USD 0.85 a year ago.
For the nine months, revenue was USD 99.87 million compared to USD 83.37 million a year ago. Net loss was USD 134.2 million compared to USD 121.51 million a year ago. Basic loss per share from continuing operations was USD 2.72 compared to USD 2.54 a year ago. Diluted loss per share from continuing operations was USD 2.72 compared to USD 2.54 a year ago.
Outset Medical, Inc. is a medical technology company. The Company offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. The Company designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by virtually anyone. The Tablo system comprises components, which include Tablo Console, Tablo Cartridge and Tablo Data Ecosystem. Tablo Console is a compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
OUTSET MEDICAL, INC. 
